Home › Compare › IUGNF vs EQR

IUGNF vs EQR: Dividend Comparison 2026

IUGNF yields 1788.91% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.96M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — IUGNF vs EQR

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IUGNF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,748,244.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + EQR for your $10,000?

IUGNF: 50%EQR: 50%
100% EQR50/50100% IUGNF
Portfolio after 10yr
$1765837991.03M
Annual income
$1,590,896,976,327,972.20/yr
Blended yield
90.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

IUGNF
No analyst data
Altman Z
-15.4
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
EQR buys
0
No recent congressional trades found for IUGNF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFEQR
Forward yield1788.91% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$3531675982.01M ✓$47.8K
Annual income after 10y$3,181,793,952,650,469.00 ✓$5,475.61
Total dividends collected$3506616114.25M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: IUGNF vs EQR ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$189,591$178,890.88$11,380$679.82+$178.2K → IUGNF
2$3,372,589$3,169,726.93$13,014$837.25+$3.36M → IUGNF
3$56,305,450$52,696,779.78$14,961$1,036.20+$56.29M → IUGNF
4$882,465,426$822,218,594.62$17,297$1,289.22+$882.45M → IUGNF
5$12,987,684,313$12,043,446,306.47$20,121$1,613.15+$12987.66M → IUGNF
6$179,550,479,073$165,653,656,858.63$23,561$2,030.84+$179550.46M → IUGNF
7$2,332,406,409,977$2,140,287,397,368.80$27,783$2,573.54+$2332406.38M → IUGNF
8$28,479,672,886,997$25,983,998,028,321.59$33,013$3,284.39+$28479672.85M → IUGNF
9$326,992,550,798,860$296,519,300,809,773.56$39,547$4,223.51+$326992550.76M → IUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$47,791$5,475.61+$3531675981.96M → IUGNF

IUGNF vs EQR: Complete Analysis 2026

IUGNF — Stock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this IUGNF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.